The ageing population and lifestyle changes bring an increased burden on health care and consequently an increase in costs. This growing cost of health care is unavoidable, and drug expenditure is forecast to increase by around 5% annually over the next 3–5 years. Increased use of generics could, however, help to offset some of this increase.
The rising cost of health care in Europe
Home/Reports
|
Posted 11/06/2010
0
Post your comment
![picture45 picture45](/var/gabi/storage/images/media/images/picture45/4646-3-eng-GB/picture45_large.jpg)
No one is denying that pharmaceuticals play an essential role in improving and maintaining health, often delaying or avoiding the need for expensive hospitalisation. However, worldwide, countries spend on average around 7% of their GDP on health care. Therefore managing and controlling costs remains a major challenge for society, including governments and healthcare insurers.
Although medicines generally constitute only around 10% of a country’s total healthcare budget (with generic medicines only comprising between 1–2%) they are a prime target for cost savings.
Generic medicines not only offer cost savings but also the ability to ensure that patients continue to receive high quality treatment at affordable prices post patent expiry. However, development costs for generic medicines are also rising, due to both the increasing complexity of the molecules that are losing protection and the rising burden of regulatory requirements.
A long-term approach involving increased use of generic medicines could compensate for some of these rising costs without compromising the health of patients. In order to achieve this, policy intervention is required by governments to secure the development of a competitive generic medicines market.
(see also, The role of generic medicines in Europe, Challenges facing generic manufacturers in Europe and Opportunities arising from increased use of generics)
Reference:
Alan Sheppard. Generic Medicines: Essential contributors to the long-term health of society. IMS Health Sector Sustainability Challenges in Europe. March 2010.
Policies & Legislation
China’s NMPA expands global ties with Netherlands and Indonesia
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Challenges and solutions in addressing the development void for oncology biosimilars
![150 AA010692 150 AA010692](/var/gabi/storage/images/media/images/150-aa0106922/21852-1-eng-GB/150-AA010692_large.jpg)
Home/Reports Posted 13/08/2024
Role of biologicals and biosimilars in cancer treatment amidst rising cases
![Cancer Cell V13I20 Cancer Cell V13I20](/var/gabi/storage/images/media/images/cancer-cell-v13i20/19527-1-eng-GB/Cancer-Cell-V13I20_large.jpg)
Home/Reports Posted 06/08/2024
FDA plans to standardize biosimilar approvals and boost access in FY 2025
![22 AA010963 22 AA010963](/var/gabi/storage/images/media/images/22-aa010963/36186-1-eng-GB/22-AA010963_large.jpg)
Home/Reports Posted 30/07/2024
The best selling biotechnology drugs of 2008: the next biosimilars targets
![picture09 picture09](/var/gabi/storage/images/media/images/picture09/2207-2-eng-GB/picture09_large.jpg)
Post your comment